Tarsus Pharmaceuticals, Inc.
TARS
$59.83
$0.180.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 128.99% | 146.71% | 182.44% | 254.45% | 449.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 128.99% | 146.71% | 182.44% | 254.45% | 449.03% |
| Cost of Revenue | 48.56% | 43.49% | 49.05% | 40.28% | 35.37% |
| Gross Profit | 164.88% | 205.25% | 293.65% | 693.70% | 1,608.80% |
| SG&A Expenses | 76.84% | 80.07% | 73.07% | 71.45% | 86.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.89% | 72.09% | 67.83% | 64.16% | 72.76% |
| Operating Income | 53.45% | 41.14% | 37.83% | 37.30% | 29.97% |
| Income Before Tax | 58.21% | 44.30% | 39.59% | 38.70% | 29.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.01% | 42.52% | 39.59% | 38.70% | 29.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.01% | 42.52% | 39.59% | 38.70% | 29.19% |
| EBIT | 53.45% | 41.14% | 37.83% | 37.30% | 29.97% |
| EBITDA | 54.51% | 42.06% | 38.61% | 37.90% | 30.42% |
| EPS Basic | 58.45% | 48.11% | 47.21% | 48.06% | 42.86% |
| Normalized Basic EPS | 64.03% | 49.93% | 46.92% | 47.78% | 44.19% |
| EPS Diluted | 58.45% | 48.11% | 47.21% | 48.06% | 42.86% |
| Normalized Diluted EPS | 64.03% | 49.93% | 46.92% | 47.78% | 44.19% |
| Average Basic Shares Outstanding | 10.77% | 11.35% | 13.54% | 16.92% | 23.60% |
| Average Diluted Shares Outstanding | 10.77% | 11.35% | 13.54% | 16.92% | 23.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |